<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003843</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067003</org_study_id>
    <secondary_id>LAC-USC-3C981</secondary_id>
    <secondary_id>NCI-G99-1513</secondary_id>
    <nct_id>NCT00003843</nct_id>
  </id_info>
  <brief_title>Irinotecan in Treating Patients With Colorectal Cancer</brief_title>
  <official_title>UGT1A1 Polymorphism in Patients With Colorectal Cancer Treated With CPT-11 (Irinotecan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Cancer Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>California Cancer Consortium</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who&#xD;
      have colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the frequency of genetic polymorphisms of UGT1 in Hispanics with colorectal&#xD;
           cancer.&#xD;
&#xD;
        -  Determine if pharmacokinetics of irinotecan and its metabolites, SN38 and SN38G, are&#xD;
           associated with the genotype of UGT1 and clinical toxicity.&#xD;
&#xD;
        -  Determine whether the genetic polymorphisms of UGT1 are associated with clinical&#xD;
           toxicity and pharmacokinetics/pharmacodynamics of irinotecan in patients with&#xD;
           unresectable colorectal cancer treated with irinotecan.&#xD;
&#xD;
        -  Determine the response, time to progression, and survival in patients with UGT1A1&#xD;
           polymorphisms treated with irinotecan.&#xD;
&#xD;
      OUTLINE: Genomic DNA is isolated from blood samples from patients and analyzed for UGT1&#xD;
      polymorphisms. Patients are stratified according to UGT1 genotype (homozygous for wild type&#xD;
      vs heterozygous for abnormal allele vs homozygous for abnormal allele).&#xD;
&#xD;
      Patients receive irinotecan over 90 minutes weekly for 4 weeks. Treatment repeats every 6&#xD;
      weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 28 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to poor accrual&#xD;
  </why_stopped>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">February 2001</completion_date>
  <primary_completion_date type="Actual">February 2001</primary_completion_date>
  <study_type>Observational</study_type>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven advanced or disseminated colorectal cancer&#xD;
&#xD;
               -  Progressive disease on fluorouracil based chemotherapy OR&#xD;
&#xD;
               -  Recurrence of disease within 12 months of adjuvant therapy with fluorouracil&#xD;
&#xD;
          -  No known CNS metastases or carcinomatous meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count greater than 1500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 3 times ULN (no greater than 5 times ULN if liver involved)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Calcium no greater than 12.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within past 6 months&#xD;
&#xD;
          -  No congestive heart failure requiring therapy&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No severe psychiatric disorders&#xD;
&#xD;
          -  No history of seizures&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No prior malignancy within past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus (random blood sugar 200 mg/dL or greater)&#xD;
&#xD;
          -  No other severe concurrent disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior oxaliplatin allowed&#xD;
&#xD;
          -  No prior irinotecan or topotecan&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz-Josef Lenz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

